Ranedis Pharmaceuticals

Ranedis Pharmaceuticals is a private biopharmaceutical company established in 2014 from the University of Notre Dame, focused on therapies for rare and lysosomal storage diseases. Program RND-001, an HDAC inhibitor with enhanced brain exposure, is in collaboration with AMO Pharma.